Takeda Pharmaceutical Co. Ltd.

Stock Exchange: XTKS • Ticker: 4502 • HQ: Osaka, Japan • Employees: 31,168 (consolidated)

Ranking by technical area
Ranking by strategic pillar


Takeda is one of the biggest risers, moving 5 places to 15th. Its access-to-medicine strategy aligns with its overall business strategy. This is not yet coupled with a solid compliance system, as evidenced by cases of misconduct settled since 2014. Takeda has strong R&D commitments related to access to medicine, and shares IP for leishmaniasis and Chagas disease. It also improves in pricing, where Takeda has newly implemented equitable pricing strategies that differentiate between countries. It newly commits not to file for or enforce patents in sub-Saharan Africa. It has not yet established a structured product donation programme. It improves in capacity building, particularly for R&D and pharmacovigilance.

Change since 2014

Has launched new access strategy supported by a centralised dashboard for tracking progress and performance.

Has been handed the largest fine following a case of misconduct of all companies in scope during the period of analysis.

Has improved its measures for ensuring clinical trials are conducted ethically and is more transparent with clinical trial data.

Implements relevant inter-country equitable pricing strategies for the first time.

Does not provide price or volume-of-sales information.

Improves its accountability for its sales agents’ pricing practices.

Newly commits to not filing for patents and to abandoning patents held in sub-Saharan Africa.

Has supported local health services in Haiti through Access to Health Project Haiti, in partnership with Partners in Health and other stakeholders.

Has improved its auditing processes related to its ad hoc product donations, which it applies to a limited selection of partners.


Engage with stakeholders to act on commitment to voluntary licensing. Takeda has a new commitment to considering the use of voluntary licensing as a mechanism for addressing the affordability and supply of on-patent and pipeline products in lower-middle income countries. It can actively seek potential partners (including manufacturers, where relevant) to explore viable opportunities for turning this commitment into action.

Implement access plans as company expands its focus. As Takeda expands its pipeline and the geographic scope of its pharmaceutical business, it can implement detailed plans for ensuring successful new products are accessible upon market approval. This can include registration targets for products targeting diseases with high burdens in low- and middle-income countries and plans to ensure affordable pricing.

Ensure the long-term sustainability of its new access strategy. Takeda can strengthen the link between access and its corporate strategies to go beyond a philanthropic approach to improving access to medicine. This would ensure the long-term sustainability of its strategy, as the company moves ahead with an increased focus on access.

Expand use of equitable pricing strategies. Takeda can expand its commitment to equitable pricing, as well as its use, to more products, e.g., azilsartan (Azilva®), a first-line treatment for hypertensive heart disease. The company can also implement intra-country equitable pricing strategies in countries with high levels of inequality and/or high out-of-pocket spending.

Join efforts to combat antimicrobial resistance. Takeda has seven antibiotics that are on the WHO Model Essential Medicines List (EML), are used in clinical practice and are important for low-resource settings. The company can take action to increase access to these medicines, while ensuring their responsible use. Takeda can join global efforts to address antimicrobial resistance, for example by signing the Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance.

Sales and operations

Takeda’s core therapeutic areas are: gastrointestinal diseases, oncology, central nervous system diseases and cardiovascular and metabolic diseases. The company’s Ethical Drug Division accounts for its largest share of sales, derived from its small presence in the consumer healthcare market. In April 2016, Takeda announced the establishment of Teva Takeda Yakuhin Ltd, a joint venture between Takeda and Teva Pharmaceutical Industries. This step is intended to allow Takeda to focus on developing innovative medicines, as this separate entity will market the company’s off-patent medicines and focus on the generic medicine market. Takeda has sales in 29 countries within the scope of the Index.

Sales in countries in scope
Sales by division
Sales by region

Portfolio and pipeline

Takeda has a mid-sized portfolio of 50 products for diseases in scope and a mid-sized pipeline of 24 R&D projects that address the needs of people in low- and middle-income countries.

Takeda’s relevant portfolio has a strong focus on non-communicable diseases (NCDs), covering diabetes, hypertensive and ischaemic heart disease and unipolar depressive disorders. The company is developing medicines and vaccines for seven communicable diseases, three neglected tropical diseases (NTDs) and five NCDs.

Takeda’s pipeline is approximately double the size it was in 2014. It has joined the new NTD Drug Discovery Booster, and several of its early-stage innovative projects for NCDs have qualified for analysis for the first time in 2016. Takeda has moved several products along its pipeline since 2014, and received regulatory approval in Japan for trelagliptin succinate (Zafatek®) for type 2 diabetes. Takeda is conducting multiple projects targeting high-priority product gaps with low commercial incentive.

Products per disease category

Most medicines in Takeda’s portfolio are for NCDs. It also has several broad-spectrum antibiotics for diseases in scope.

Pipeline projects

Takeda participates in several R&D projects with the Global Health Innovative Technology (GHIT) Fund that require products be made available in relevant countries at reasonable prices or are licensed out royalty-free.

First-line treatments and essential medicines

A comparatively high proportion of Takeda’s relevant products are listed on the WHO EML and/or as first-line treatments: e.g., azilsartan (Azilva®) and candesartan for hypertensive heart disease.

Pipeline by stage of development
– Innovative medicines and vaccines

Takeda’s relevant pipeline concentrates on innovative medicines and vaccines. Its projects are mainly in early stages of development, targeting 17 diseases, with a focus on schizophrenia.

Pipeline by stage of development
– Adaptive medicines and vaccines

Takeda is adapting one product, for malaria, which targets the needs of people living in low- and middle-income countries.

Please refer to the pdf of the report card (that can be downloaded here) for information on Takeda’s performance per technical area.

Sign up to receive updates about our work.